Cerebellar rTMS for Essential Tremor

Essential Tremor Clinical Trial

Official title:

Assessing Clinical Effectiveness of Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) on Severity of Motor Signs of Essential Tremor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02704793
• Other study ID #: 940597
• Status: Completed
• Phase: N/A
• Start date: April 2016
• Est. completion date: May 2018

Study information

• Verified date: May 2018
• Source: Mashhad University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Essential tremor (ET) is a low-mortality, though truly burdensome and debilitating condition which is known to be the second most common movement disorder of the adult population only after restless legs syndrome. The prevalence of the disorder in all age groups has been estimated to be 0.9%. Repetitive transcranial magnetic stimulation (rTMS) is an almost safe technique which has been used in diagnosis and treatment of many neurologic and psychiatric conditions. Recent studies have shown that cerebellum has a significant role in development of ET and that rTMS could exert therapeutic effects on its motor symptoms. In this study researchers will recruit at least 30 subjects among patients visiting at the Specialty Clinic of Mashhad Medical University according to researchers exclusion and inclusion criteria and after signing a written informed consent, will randomly be assigned to either real or sham rTMS. On the real rTMS arm, patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days and sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS. Subject's ear will be protected with earplugs during both real and sham stimulations. After 2 months of follow-up, patients will undergo crossover and receive the other treatment as described above. Patients would be assessed using Fahn-Tolosa-Marin scale at the baseline and again on days 5, 12, and 30 after each real or sham treatment session by a blinded researcher. Data will be analysed by another researcher who is also blind.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: May 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• having a diagnosis of essential tremor (ET) based on Movement Disorder Society criteria, involving at least one hand.

• 18 years or above

• cognitively eligible to give informed consent of participation in the trial.

Exclusion Criteria:

• Cardiac pace-maker or other implanted magnetic device or having other contraindications of performing a routine non-contrast MRI

• skin defect at the occipital area preventing placement of a coil

• Currently pregnant or plan for pregnancy in the next 6 months

• History of seizure

• Other comorbid medical conditions capable of producing or enhancing tremor

• advanced cardiac, renal, hepatic or other disabling conditions making patient physical unable to participate in examination and receiving the intervention

• Use of new drugs with potential effect on tremor

Related Conditions & MeSH terms

• Essential Tremor
• Tremor

Intervention

Other:
• Bilateral 1 Hz Cerebellar rTMS
900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.
• Sham (electrical stimulation)
900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.

Locations

Country	Name	City	State
Iran, Islamic Republic of	Department of Neurology, Ghaem Hospital	Mashhad	Razavi Khorasan

Sponsors (1)

Lead Sponsor	Collaborator
Mashhad University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in score of Fahn-Tolosa-Marin scale		at the baseline and on days 5, 12, and 30 after each real or sham treatment session.

External Links

•   Published study protocol